Shares of Strides Pharma Ltd. are off the highs of the day after the drugmaker reported results for the June quarter on Tuesday, July 29.The company reported a 7% growth in US sales for the quarter, in comparison to the same quarter last year, to $70 million.
In rupee terms, the company’s revenue went up by 6.2% year-on-year to ₹1,119.7 crore.
Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) for the quarter increased by 14.7% from the year-ago quarter to ₹217.9 crore, while margins expanded by 150 basis points to 19.5% from 18% last year.
The company reported an exceptional loss of ₹8.4 crore during the quarter, in comparison to an exceptional gain of ₹98.4 crore.Strides also had a one-time gain of ₹3,188 crore during the quarter.
In rupee terms, the company’s revenue went up by 6.2% year-on-year to ₹1,119.7 crore.
Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) for the quarter increased by 14.7% from the year-ago quarter to ₹217.9 crore, while margins expanded by 150 basis points to 19.5% from 18% last year.
The company reported an exceptional loss of ₹8.4 crore during the quarter, in comparison to an exceptional gain of ₹98.4 crore.Strides also had a one-time gain of ₹3,188 crore during the quarter.
Gross margins for the quarter increased by 300 basis points from the same quarter last year to 60.3%.
“Our focus on cost management and diligent execution has enabled us to deliver robust results,” said Badree Komandur, MD & Group CEO of Strides Pharma. He added that the company will enhance its R&D efforts during the year to drive sustainable, long-term growth.
Shares of Strides Pharma are trading 3.2% higher on Tuesday, after the results announcement, to trade at ₹952. The stock has gained 6% in the last one month.
First Published: Jul 29, 2025 12:56 PM IS
